TNFRSF17 and plasma cell myeloma: BCMA expression was also assessed in myeloma cells pre- and post-treatment and patient 11 was found to have BCMAnegative myeloma cells at week 56 post-infusion followed by myeloma progression at week 68 with mixed BCMA expression (29) (Tables 1, 2).